<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370316</url>
  </required_header>
  <id_info>
    <org_study_id>GR-2011-02351347</org_study_id>
    <nct_id>NCT02370316</nct_id>
  </id_info>
  <brief_title>Biomarkers of Change in BPD After Metacognitive Interpersonal Therapy-standard Approach</brief_title>
  <acronym>CLIMAMITHE</acronym>
  <official_title>Neuroimaging and Clinical Markers of Change in Borderline Personality Disorder After Metacognitive Interpersonal Therapy - Standard Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Centro San Giovanni di Dio Fatebenefratelli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Centro San Giovanni di Dio Fatebenefratelli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present randomised clinical trial aims to assess the clinical and neurobiological changes
      following Metacognitive Interpersonal Therapy -standard approach (MIT-SA) compared with
      Clinical Structured Treatment (CST) derived from specific recommendations in APA guidelines
      for borderline personality disorder (BPD). The investigators will assess clinical changes in
      metacognitive abilities and in emotion regulation and changes in brain activation patterns at
      the resting state and while they view emotional pictures. A multidimensional assessment will
      be performed at the baseline, at 6, 12, 18 months. The investigators will take structural and
      functional Magnetic Resonance Images (MRIs) in MIT-Treated BPD (N=30) and CST-treated BPD
      (N=30) at baseline and after treatment, as well as a group of 30 healthy and unrelated
      volunteers that will be scanned once for comparison. Furthermore, blood analyses will be done
      in order to assess level of BDNF and some hormone levels (oxytocin and vasopressin) before
      and after treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly allocate to two kind of interventions: MIT-SA and CST. Patients
      will be enrolled in 3 centres: Unit of Psychiatry, IRCCS San Giovanni di Dio-FBF, Brescia;
      Terzo Centro di Psicoterapia Cognitiva-School of Cognitive Psychotherapy, Rome; Mental Health
      Department ASL Roma G, Rome, Italy.

      A multidimensional evaluation with standardized tools will assess: level of psychopathology,
      depression, anger, impulsiveness, level of functioning. In particular, the assessment will
      include: the Structured Clinical Interview for DSM disorder; the Difficulties in Emotion
      Regulation Scale (DERS) (primary outcome); Metacognition Assessment Interview to assess
      metacognitive functions. Neuropsychological assessment will assess different cognitive
      domains, empathy and emotional recognition with standardized tools . Additionally, the
      emotional priming paradigm to evaluate emotion processing will be included.

      Data on demographics, traumatic exposure, suicide attempts, self-injury and aggression
      episodes, hospitalizations, and pharmacotherapy will be collected. Structural and functional
      MRI will be collected in MIT-Treated BPD (N=30) and CST-treated BPD (N=30) at baseline and
      after treatment. Healthy volunteers (N=30) will be scanned once for comparison. Specific MRI
      analyses:1) Whole brain (cortical thickness) analyses will be conducted to explore the
      correlates of psychotherapy and treatment response. Functional connectivity studies will
      consider A) activity at rest, both before and after treatment; B) functional activation in
      response to standardized emotional material from the International Affective Pictures System
      (IAPS). 2) Region of interest analyses: regions of particular elevance (hippocampus,
      amygdale, insula) will be studied using advanced neuroimaging tools.

      Blood samples will be collected in order to assess variations in levels of BDNF and some
      hormones (oxytocin and vasopressin) pre- and post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Clinical changes in metacognitive abilities and in emotion regulation assessed with the Difficulties in Emotion Regulation Scale (DERS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in metacognitive abilities (assessed with the Metacognition Assessment Interview)</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>Clinical changes in metacognitive abilities assessed with the Metacognition Assessment Interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in activation in the amygdala at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change from Baseline in activation in the amygdala at 12 months in response to standardized emotional material from the International Affective Pictures System</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>MIT - SA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical Structured Treatment (CST)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Metacognitive Interpersonal Therapy (MIT-SA)</intervention_name>
    <description>MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)</description>
    <arm_group_label>MIT - SA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Clinical Structured Treatment</intervention_name>
    <description>structured case management and symptom-targeted medication</description>
    <arm_group_label>Clinical Structured Treatment (CST)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM 5 criteria for BPD

          -  Able to provide informed consent

        Exclusion Criteria:

          -  lifetime diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder,
             organic mental syndromes;

          -  active substance abuse or dependence in the 6 months before the enrolment;

          -  concurrent psychotherapy;

          -  cognitive impairment or dementia;

          -  relevant neurological signs;

          -  pregnancy/lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta Rossi, PsyD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Centro San Giovanni di Dio - FBF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Rossi, PsyD</last_name>
    <phone>+39 030 3501719</phone>
    <email>rrossi@fatebenefratelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariangela Lanfredi, PsyD</last_name>
    <phone>+39 030 3501504</phone>
    <email>mlanfredi@fatebenefratelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Irccs Centre San Giovanni di Dio - Fatebenefratelli</name>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Rossi, Psycologist</last_name>
      <phone>+39 030 3501719</phone>
      <email>rrossi@fatebenefratelli.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Semerari A, Cucchi M, Dimaggio G, Cavadini D, Carcione A, Battelli V, Nicol√≤ G, Pedone R, Siccardi T, D'Angerio S, Ronchi P, Maffei C, Smeraldi E. The development of the Metacognition Assessment interview: instrument description, factor structure and reliability in a non-clinical sample. Psychiatry Res. 2012 Dec 30;200(2-3):890-5. doi: 10.1016/j.psychres.2012.07.015. Epub 2012 Aug 18.</citation>
    <PMID>22906953</PMID>
  </reference>
  <reference>
    <citation>Rossi R, Lanfredi M, Pievani M, Boccardi M, Rasser PE, Thompson PM, Cavedo E, Cotelli M, Rosini S, Beneduce R, Bignotti S, Magni LR, Rillosi L, Magnaldi S, Cobelli M, Rossi G, Frisoni GB. Abnormalities in cortical gray matter density in borderline personality disorder. Eur Psychiatry. 2015 Feb;30(2):221-7. doi: 10.1016/j.eurpsy.2014.11.009. Epub 2015 Jan 2.</citation>
    <PMID>25561291</PMID>
  </reference>
  <reference>
    <citation>Rossi R, Pievani M, Lorenzi M, Boccardi M, Beneduce R, Bignotti S, Borsci G, Cotelli M, Giannakopoulos P, Magni LR, Rillosi L, Rosini S, Rossi G, Frisoni GB. Structural brain features of borderline personality and bipolar disorders. Psychiatry Res. 2013 Aug 30;213(2):83-91. doi: 10.1016/j.pscychresns.2012.07.002. Epub 2012 Nov 10.</citation>
    <PMID>23146251</PMID>
  </reference>
  <reference>
    <citation>Rossi R, Lanfredi M, Pievani M, Boccardi M, Beneduce R, Rillosi L, Giannakopoulos P, Thompson PM, Rossi G, Frisoni GB. Volumetric and topographic differences in hippocampal subdivisions in borderline personality and bipolar disorders. Psychiatry Res. 2012 Aug-Sep;203(2-3):132-8. doi: 10.1016/j.pscychresns.2011.12.004. Epub 2012 Sep 1.</citation>
    <PMID>22944368</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Centro San Giovanni di Dio Fatebenefratelli</investigator_affiliation>
    <investigator_full_name>Roberta Rossi</investigator_full_name>
    <investigator_title>psyD</investigator_title>
  </responsible_party>
  <keyword>metacognition</keyword>
  <keyword>MRI</keyword>
  <keyword>Psychotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

